TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38320198

Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=446)
Number of subjects: 917

Group type: COMPARATOR
Intervention: Usual care (n=471)
Number of subjects: 917
Study: 38320207

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 38320238

Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Wait-and-see
Number of subjects: 64
Study: 38320240

Group type: EXPERIMENTAL
Intervention: Interfascial injection of 10 mL of 10% dextrose water
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham injection of 0.5 mL of 10% dextrose water
Number of subjects: 35
Study: 38320248

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 19
Study: 38320431

Group type: EXPERIMENTAL
Intervention: Peposertib 200 mg b.i.d. plus avelumab
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Peposertib 250 mg q.d. plus avelumab and radiotherapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicity (DLT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Recommended phase II dose (RP2D) and maximum tolerated dose (MTD)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of peposertib
Number of subjects: 44
Study: 38320464

Group type: EXPERIMENTAL
Intervention: Uncontrolled glycemia (glucose levels ≥175 mg/dL)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Controlled glycemia (glucose levels <175 mg/dL)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Uncontrolled glycemia
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Higher fasting glucose and HbA1C levels
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Participants with T2DM
Number of subjects: 97
Study: 38320487

Group type: EXPERIMENTAL
Intervention: Optimized digital health intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unoptimized digital health intervention
Number of subjects: 0
Study: 38320486

Group type: EXPERIMENTAL
Intervention: nab-P/Gem-mFOLFOX
Number of subjects: 157

Group type: COMPARATOR
Intervention: nab-P/Gem
Number of subjects: 157
Study: 38320488

Group type: EXPERIMENTAL
Intervention: Two-dose 9vHPV vaccine (0 and 6 months)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Three-dose 9vHPV vaccine (0, 2, and 6 months)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Two-dose 9vHPV vaccine
Number of subjects: 438

Group type: COMPARATOR
Intervention: Three-dose 9vHPV vaccine
Number of subjects: 438
Study: 38320489

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4017

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4017
Study: 38320499

Group type: EXPERIMENTAL
Intervention: Caffeine and LISA
Number of subjects: 180

Group type: COMPARATOR
Intervention: Caffeine and CPAP
Number of subjects: 180
Study: 38320498

Group type: EXPERIMENTAL
Intervention: ARO-APOC3 10 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ARO-APOC3 25 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ARO-APOC3 50 mg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ARO-APOC3 100 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 38320500

Group type: EXPERIMENTAL
Intervention: 5 mg of dapagliflozin
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 2.5 mg of saxagliptin
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 245
Study: 38320501

Group type: COMPARATOR
Intervention: Leuprolide alone
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Combination (enzalutamide plus leuprolide)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Monotherapy (enzalutamide)
Number of subjects: 1068
Study: 38320511

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 352

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 352
Study: 38320513

Group type: EXPERIMENTAL
Intervention: ODM-208 5 mg twice daily with glucocorticoid/mineralocorticoid replacement
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ODM-208 5 mg twice daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 92
Study: 38320524

Group type: EXPERIMENTAL
Intervention: Difelikefalin 0.5 μg/kg intravenously three times per week for 6 weeks
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Difelikefalin
Number of subjects: 178
Study: 38320525

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11007
Study: 38320526

Group type: EXPERIMENTAL
Intervention: PTAH (peanut allergen powder-dnfp)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: PTAH
Number of subjects: 146
Study: 38320527

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nafamostat
Number of subjects: 160
Study: 38320723

Group type: EXPERIMENTAL
Intervention: Remote interactive telemedicine session and online genetic education
Number of subjects: 601

Group type: COMPARATOR
Intervention: Online genetic education only
Number of subjects: 601
Study: 38320840

Group type: EXPERIMENTAL
Intervention: Rapid genomic sequencing (rGS)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Education about genomic medicine provided to neonatal providers
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Clinical interpretive reports created by the study team
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Follow-up of families for 12 months
Number of subjects: 250
Study: 38321023

Group type: EXPERIMENTAL
Intervention: agenT-797 (donor-unrestricted allogeneic ex vivo expanded iNKT cell therapy)
Number of subjects: 21
Study: 38321085

Group type: EXPERIMENTAL
Intervention: IMU-based gait analysis during the 2-min walk test (2mWT)
Number of subjects: 26
Study: 38321153

Group type: EXPERIMENTAL
Intervention: Smartphone application-based rehabilitation for chronic respiratory disease (n=41)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Smartphone application-based rehabilitation for cardiovascular disease (n=52)
Number of subjects: 93
Study: 38321218

Group type: EXPERIMENTAL
Intervention: OMO-103 (6.48 mg/kg, DL5)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: OMO-103 (DL5)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: OMO-103
Number of subjects: 22
Study: 38321220

Group type: EXPERIMENTAL
Intervention: UBX1325 (foselutoclax), a senolytic small-molecule inhibitor of BCL-xL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38321223

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with systemic treatment
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) alone
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) as 2nd or further treatment-line
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Partition model dosimetry
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: No extrahepatic disease, no ascites, <6.1 months from diagnosis to treatment
Number of subjects: 174
Study: 38321316

Group type: EXPERIMENTAL
Intervention: Mobile-based version of a feeding-focused childhood obesity prevention program
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: In-person attendance at nutrition education classes
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Online engagement with videos
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Demographic correlates of parent engagement
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Online engagement by ethnicity and acculturation
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: In-person attendance by acculturation
Number of subjects: 168
Study: 38321372

Group type: EXPERIMENTAL
Intervention: Vascular parkinsonism (VaP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 104

Group type: COMPARATOR
Intervention: Parkinson's disease (PD)
Number of subjects: 104
Study: 38321454

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Miconazole-loaded chitosan nanoparticles
Number of subjects: 80
Study: 38321472

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 38321482

Group type: EXPERIMENTAL
Intervention: Malkia Klabu program
Number of subjects: 40
Study: 38321507

Group type: EXPERIMENTAL
Intervention: Continuous non-invasive blood pressure monitoring (C-NiBP)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Intermittent non-invasive blood pressure monitoring (I-NiBP)
Number of subjects: 1265
Study: 38321529

Group type: EXPERIMENTAL
Intervention: Thiamine administration
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Thiamine administration in thiamine-deficient group
Number of subjects: 158
Study: 38321567

Group type: EXPERIMENTAL
Intervention: SKY Schools intervention (social-emotional learning combined with Sudarshan Kriya Yoga)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SKY Schools intervention
Number of subjects: 49
Study: 38321576

Group type: EXPERIMENTAL
Intervention: Carers-ID online intervention (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control (n = 60)
Number of subjects: 120
Study: 38321617

Group type: EXPERIMENTAL
Intervention: Posttreatment overvaluation of shape/weight
Number of subjects: 129

Group type: COMPARATOR
Intervention: Behaviorally-based treatments
Number of subjects: 129
Study: 38321811

Group type: EXPERIMENTAL
Intervention: Immunotherapy (e.g., durvalumab, atezolizumab, nivolumab, pembrolizumab, tremelimumab, ipilimumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted therapies (e.g., tyrosine kinase inhibitors, monoclonal antibody immune checkpoint inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokines, cancer vaccines, adoptive T cell therapies, Natural killer cell therapies
Number of subjects: 0
Study: 38322553

Group type: EXPERIMENTAL
Intervention: AllerPops prebiotic supplements
Number of subjects: 72
Study: 38322707

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) and Model of Goal-Directed Behavior (MGB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Past efforts to control blood pressure
Number of subjects: 0
Study: 38322862

Group type: EXPERIMENTAL
Intervention: Esketamine infusion (0.75 mcg/ml) combined with sufentanil (1.5 mcg/ml) for 24 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (sufentanil 1.5 mcg/ml alone)
Number of subjects: 80
Study: 38322981

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 25 mg 3 times/day if <80 kg and 50 mg 3 times/day if >80 kg for 14 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 99
Study: 38323147

Group type: EXPERIMENTAL
Intervention: Baltimore Urban food Distribution (BUD) application
Number of subjects: 0
Study: 38323173

Group type: EXPERIMENTAL
Intervention: Intravenous fosaprepitant (arm A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral aprepitant (arm B)
Number of subjects: 108
Study: 38323410

Group type: EXPERIMENTAL
Intervention: Serum exosomal miRNA classifier (Cmi) comprising 3 miRNAs (miR-4265, 1208, 3127-5p)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Cmi in post-ERCP pancreatitis cases
Number of subjects: 743

Group type: COMPARATOR
Intervention: AP patients without POF (control group)
Number of subjects: 743
Study: 38323417

Group type: EXPERIMENTAL
Intervention: Endovascular repair using multi-branched off-the-shelf devices (Zenith t-branch, Cook Medical Inc.) in 88 patients, physician-modified endografts in 8 patients, patient-specific device or parallel grafts in 2 patients each.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endovascular repair of rTAAA
Number of subjects: 100
Study: 38323455

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurement (ABPM)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) velocity
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cardiovascular assessment
Number of subjects: 41
Study: 38323513

Group type: EXPERIMENTAL
Intervention: Personalized amlodipine dose titration (novel doses: 1, 2, 3, 4, 6, 7, 8, 9 mg; standard doses: 5 and 10 mg) over 14 weeks.
Number of subjects: 205
Study: 38323608

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Serum amyloid A
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Interleukin-4 (IL-4)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Interleukin-1α (IL-1α)
Number of subjects: 156
Study: 38323656

Group type: EXPERIMENTAL
Intervention: Presence of fragmented QRS complex (fQRS)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Presence of inferior ST-T change
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Low- and intermediate-risk CTD-PAH with inferior ST-T change
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curve analysis
Number of subjects: 141
Study: 38323738

Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 0
Study: 38323784

Group type: EXPERIMENTAL
Intervention: Free-Breathing Accelerated Cine Deep Learning Reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Breath-Hold Cardiac MRI Sequences
Number of subjects: 0
Study: 38323855

Group type: EXPERIMENTAL
Intervention: Tenapanor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38323949

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-based Creating Opportunities for Personal Empowerment program
Number of subjects: 299

Group type: COMPARATOR
Intervention: Health promotion content
Number of subjects: 299
Study: 38324012

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedentary behaviors
Number of subjects: 0
Study: 38324085

Group type: EXPERIMENTAL
Intervention: Navarixin 30 mg plus pembrolizumab
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Navarixin 100 mg plus pembrolizumab
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Navarixin 30 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Navarixin 100 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Navarixin plus pembrolizumab
Number of subjects: 105
Study: 38324241

Group type: EXPERIMENTAL
Intervention: Data-to-care strategy using a disease intervention specialist (DIS)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 655
Study: 38324254

Group type: EXPERIMENTAL
Intervention: Influential patients in hemodialysis clinics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38324280

Group type: EXPERIMENTAL
Intervention: β-blocker withdrawal
Number of subjects: 52
Study: 38324314

Group type: EXPERIMENTAL
Intervention: Atlantic diet intervention (educational sessions, cooking classes, written material, and foods characteristic of the Atlantic diet)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Control group (habitual lifestyle)
Number of subjects: 574
Study: 38324313

Group type: EXPERIMENTAL
Intervention: MRI-targeted group (including screening using biomarkers and MRI)
Number of subjects: 1500
Study: 38324336

Group type: EXPERIMENTAL
Intervention: ADCT-602
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADCT-602 + pacritinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chidamide
Number of subjects: 0
Study: 38324365

Group type: EXPERIMENTAL
Intervention: ACTION intervention (group sessions, physical activity self-monitoring-Fitbit, and text-based support for step goal setting)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Education control (an individual asthma education session and SMS text messages related to asthma education)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: ACTION intervention
Number of subjects: 224
Study: 38324367

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based treatment app (Spark)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Psychoeducational control app (control)
Number of subjects: 168
Study: 38324414

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 336
Study: 38324415

Group type: EXPERIMENTAL
Intervention: Apixaban, 5 mg or 2.5 mg, twice daily (n=507)
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Aspirin, 81 mg, once daily (n=508)
Number of subjects: 1015
Study: 38324484

Group type: EXPERIMENTAL
Intervention: JNJ-77242113 25 mg once daily
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: JNJ-77242113 25 mg twice daily
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: JNJ-77242113 50 mg once daily
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: JNJ-77242113 100 mg once daily
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: JNJ-77242113 100 mg twice daily
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 38324483

Group type: EXPERIMENTAL
Intervention: 80 mg resmetirom
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: 100 mg resmetirom
Number of subjects: 966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 966
Study: 38324512

Group type: EXPERIMENTAL
Intervention: Providence-type brace optimized by the semi-automatic algorithm leveraging a patient-specific FEM (Test)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional Providence-type brace (Control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Providence-type brace optimized by the semi-automatic algorithm (Test)
Number of subjects: 58
Study: 38324584

Group type: EXPERIMENTAL
Intervention: Client-directed intervention (free ACT for positive RDT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined client and provider-directed intervention (free ACT for positive RDT and $0.1 for each RDT performed)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control arm (subsidized mRDT testing at $0.4)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Client-directed intervention and combined intervention
Number of subjects: 39
Study: 38324741

Group type: EXPERIMENTAL
Intervention: Crenolanib plus intensive chemotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intensive chemotherapy alone (control group)
Number of subjects: 44
Study: 38324744

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study: 38324766

Group type: EXPERIMENTAL
Intervention: mRNA-1647
Number of subjects: 0

Group type: COMPARATOR
Intervention: gB/MF59
Number of subjects: 0
Study: 38325276

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 38325290

Group type: EXPERIMENTAL
Intervention: Penicillin Skin Testing (PST) followed by amoxicillin 250 mg challenge
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Graded Oral Challenge (GOC) with amoxicillin 25 mg followed by 250 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Overall study completion
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Provider surveys
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Risk-assessment questionnaire
Number of subjects: 206
Study: 38325328

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks in conjunction with glass yttrium-90 (Y90) radioembolization TheraSphere
Number of subjects: 27
Study: 38325411

Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir (GLE/PIB)
Number of subjects: 115
Study: 38325518

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Individual and Group Supportive Therapy (IGST)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both DBT and IGST
Number of subjects: 173
Study: 38325649

Group type: EXPERIMENTAL
Intervention: Bone microarchitecture in people with SCI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unloading
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fracture prevention strategies
Number of subjects: 20
Study: 38325673

Group type: EXPERIMENTAL
Intervention: Cumulated Ambulation Score (CAS) assessed by two independent physiotherapists
Number of subjects: 60
Study: 38325765

Group type: EXPERIMENTAL
Intervention: Protein intake of 1.08 g⋅kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 38325896

Group type: EXPERIMENTAL
Intervention: Local coalitions with training and technical assistance for smoke-free policy development and enforcement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 28
Study: 38325988

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) combined with medical therapy (MT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy (MT) alone
Number of subjects: 100
Study: 38326228

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 566

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 566
Study: 38326260

Group type: EXPERIMENTAL
Intervention: Incremental Step Test (IST)
Number of subjects: 63
Study: 38326267

Group type: EXPERIMENTAL
Intervention: Integrated intervention package including peer support, mobile phone messaging, and birthing kits during pregnancy
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Routine government health services (standard of care)
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Integrated intervention package
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Integrated intervention package and Routine government health services
Number of subjects: 1877
Study: 38326271

Group type: EXPERIMENTAL
Intervention: Online CPR-AED training
Number of subjects: 0